Abbott allegedly engaged in unfair and deceptive practices when it marketed its drug, Depakote, for treatments that were not approved by the FDA. Depakote is approved for treatment of seizure disorders, mania associated with bipolar disorder and prophylaxis of migraines, but the State alleged Abbott marketed the drug for treating unapproved uses, including schizophrenia, agitated dementia and autism. As a result of the investigation, Abbott has agreed to significantly change how it markets Depakote and to cease promoting off-label uses, which was in violation of the Tennessee Consumer Protection Act. This was a multistate case.
This list includes only significant filings and is not intended to be a complete record of the matter.